Project Grant R44PS005188

This Project Grant award of $884,453.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a rapid, cost-effective point-of-care (POC) test for detecting the hepatitis C virus (HCV). The project, titled "Rapid Point of Care Hepatitis C Virus Detection Using a Long-Lasting Luminescent Cascade Signal Amplification," is being conducted by Brigham & Women's Hospital...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $876,400 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Notre Dame DU Lac to develop a novel point-of-care diagnostic assay for rapid assessment of hepatitis C virus (HCV) viral load and associated liver disease. The project aims to integrate Janus bead technology and virus ultrafiltration to create a 30-minute, one-step assay that can quantify HCV viral load...

This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an economical, rapid, and accurate molecular test for detecting hepatitis C virus (HCV) and HIV infections from whole blood samples. The $1,361,442 award to Emory University will fund research to: 1) automate and streamline RNA sample extraction and stabilization technology for HCV and HIV RNA...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a low-cost, instrument-free rapid antigen test for active Hepatitis C Virus (HCV) infection. The $272,133 award to Rutgers, The State University of New Jersey will fund research activities over a period of approximately 2 years, from June 2025 to May 2027. The key objectives are to characterize the...

This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $592,027 to Northwestern University to develop and validate a point-of-care molecular diagnostic test for active hepatitis C virus (HCV) infection. The key products and services to be delivered include: Development of the "DASH HCV" test that can rapidly detect HCV viral RNA from a simple finger-stick blood sample, without the...

This $249,000 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of a novel split enzyme diagnostic platform for rapid, sensitive detection of protein and small molecule biomarkers at the point of care. The key objectives of this 3-year project are to: 1) incorporate binding domains into a split adenylate...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop an integrated biosensor technology for the simultaneous detection of HIV, hepatitis B, and hepatitis C viruses. The $537,619 award, spanning from March 2025 to February 2028, will support the University of Central Florida's research to integrate their recently developed four-way junction (4WJ) electrochemical...

The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, has awarded a $324,962 Project Grant to Tetmedical, Inc. to develop a technology for rapid, point-of-care and at-home testing of liver enzyme levels. The goal is to enable convenient and timely monitoring of drug-induced liver injury (DILI) and other sources of liver damage. The project aims to optimize tethered enzyme assays for detecting aspartate aminotransferase (AST) and alanine aminotransferase (ALT),...

This $389,782 Cooperative Agreement award from the United States Department of Agriculture's Animal and Plant Health Inspection Service (APHIS), under the Plant and Animal Disease, Pest Control, and Animal Care program (CFDA 10.025), aims to develop highly specific and validated TaqMan assays for the simultaneous detection of two critical shrimp diseases: Hepatopancreatic Microsporidiosis (HPM) caused by Enterocytozoon hepatopenaei (EHP) and Acute Hepatopancreatic Necrosis Disease (AHPND) caused...

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $606,500 Project Grant to Kephera Diagnostics LLC, a for-profit limited liability company, to develop a two-minute rapid assay platform for point-of-care diagnosis. This grant is funded under the CDC's Investigations and Technical Assistance program (CFDA 93.283), which supports research, surveillance, and innovative healthcare technologies to address public health challenges. The grant award will enable Kephera Diagnostics to...